Published in Law and Health Weekly, April 30th, 2005
In August 2004, Halozyme Therapeutics and Baxter Healthcare Corp. signed an exclusive sales and marketing agreement, under which Baxter and Halozyme are equal partners in the commercialization of Enhanze SC, upon U.S. Food and Drug Administration (FDA) approval. Upon approval of the therapeutic by the FDA,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly